Public filings / PTGX on Yahoo Finance (opens in a new tab)
PTGX: insider buying, 13F holders, analyst moves
Protagonist Therapeutics Inc
A summary of public filings about Protagonist Therapeutics Inc. For the latest insider history, price chart, analyst changes and activist filings, open the live lookup.
SEC Form 13F · Q2 2026
5 of our 100 managers hold PTGX
Combined reported value $1.55B; 1 sold out since Q1 2026.
Holders among our 100 managers: 3 in Q3 2023, 5 in Q2 2026.
| Manager | Value | % of portfolio | Change vs Q1 2026 |
|---|---|---|---|
| Farallon Capital | $778.2M | 4.56% | Unchanged |
| RTW Investments | $620.4M | 5.30% | Unchanged |
| Perceptive Advisors | $120.4M | 1.87% | Trimmed |
| Duquesne Family Office | $25.6M | 0.59% | Added |
| Polen Capital | $2.8M | 0.02% | Trimmed |
Important information
Facts from public SEC filings, shown for information only. Not a recommendation. Not individualized investment advice. Gulfstream Capital and its clients may hold positions in securities shown.